Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 With A Partially Blinded Extension Period To Evaluate The Efficacy And Safety Of Pf-06651600 And Pf-06700841 In Subjects With Active Non-segmental Vitiligo

Trial Profile

A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 With A Partially Blinded Extension Period To Evaluate The Efficacy And Safety Of Pf-06651600 And Pf-06700841 In Subjects With Active Non-segmental Vitiligo

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs PF 6651600 (Primary) ; PF 6700841 (Primary)
  • Indications Vitiligo
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Jan 2019 Planned End Date changed from 7 Dec 2020 to 17 Mar 2021.
    • 08 Jan 2019 Planned primary completion date changed from 15 Jun 2020 to 23 Sep 2020.
    • 10 Dec 2018 Planned End Date changed from 21 Oct 2020 to 7 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top